Altre lingue RepliCel Life Sciences Inc.

Azioni

REPCF

CA76027P4006

Mercato chiuso - OTC Markets Altri mercati azionari 16:20:42 15/03/2024			Variaz. 5gg	Var. 1 gen.
0,0428 ^USD	+4,99%		-.--%	-4,89%

2023	RepliCel Life Sciences Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2023	CI
2023	RepliCel Life Sciences Inc. riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 30 giugno 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

RepliCel Life Sciences : Announces Secured Loan Agreement	18/04
RepliCel Life Sciences Inc. Announces Secured Loan Agreement	18/04
RepliCel Life Sciences : announces a Letter of Intent for Asset Purchase Agreement - Form 6-K	20/03
RepliCel Life Sciences : Letter of Intention (Asset Purchase)	18/03
Canadian Investment Regulatory Organization Trading Halt - RP	15/03
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	30/11
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11
RepliCel Life Sciences : Arbitration decision	16/11
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	24/10/23
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/10/23
RepliCel Life Sciences : AGM 2023 Zoom Link and Materials	22/09/23
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director	30/08/23
RepliCel Life Sciences : Notice of Meeting and Record Date - Form 6-K	17/08/23
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors	17/08/23
RepliCel Life Sciences Inc. Announces Chief Financial Officer Changes	17/08/23
REPLICEL LIFE SCIENCES : STATEMENT OF EXECUTIVE COMPENSATION - Form 6-K	10/08/23
RepliCel Life Sciences : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	31/05/23
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	30/05/23
RepliCel Life Sciences : Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options - Form 6-K	18/05/23
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	02/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue RepliCel Life Sciences Inc.

Azioni

REPCF

CA76027P4006

Altre lingue

Filtri